Sock-it 2 Hunter Syndrome

02/11/2022

💜💜💜

12/10/2020

💜💜💜

Exciting news from REGENXBIO! Their RGX-121 clinical trial for the treatment of MPS II (Hunter Syndrome) has returned positive interim data for the first two cohorts of patients, and a third cohort with increased dosage will begin enrolling patients in the first quarter of 2021. RGX-121 is designed to deliver the gene that encodes the missing enzyme iduronate-2-sulfatase (I2S) directly to the central nervous system of individuals with MPS II. Read the full press release here:
https://mpssociety.org/wp-content/uploads/2020/12/RGX-121-Press-Release_December-2020_clean.pdf

10/01/2020

Amazing news from RegenxBio! They are expanding their gene therapy trial to boys with Hunter Syndrome ages 5-18! 💜💜💜

- Ongoing Phase I/II trial to enroll up to 6 additional patients in Cohort 2 while planning for next steps in program; further trial updates expected by the end of 2020 - New IND for Phase I/II trial cleared by FDA to evaluate RGX-121 in patients with severe MPS II ages 5-18 years old and

05/14/2020

May 15th is MPS Awareness Day. Please wear purple or your Sock-it 2 Hunter Syndrome gear tomorrow in support of Aiden, Ethan and their friends fighting this horrific disease. Spread awareness and tag us in those photos! 💜

05/03/2020

2 years and 27 days... that's how old Ethan was when he was diagnosed with MPS II Hunter Syndrome.

We are posting this to raise awareness for , , and the “signs” that lead to diagnosis. Our first sign something was awry was when Ethan’s speech was delayed and he suffered from constant ear infections. Help us spread the word and , leading up to MPS Awareness Day on May 15, 2020!

Copy and paste this text with your own photo, signs, and age of diagnosis. Try and tag FIVE (or six 😁) more people and challenge them to do the same!